Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Drug Development
466 Articles Available
1
20
Can't find what you're looking for? Try our
advanced search
.
ViiV Healthcare Announces Phase III Study Meets Primary Endpoint
PR-M07-19-NI-032
Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease
PR-M07-19-NI-031
Gut–Brain Axis
Harnessing the Gut–Brain Axis to Treat Neurological Disorders
PAO-07-2019-CL-002
Drug Development
Looking Beyond Current Treatments for CNS Diseases and Disorders
PAO-07-2019-CL-003
FDA Approval
FDA Grants Additional Myeloma Approval to J&J’s Darzalex
PAO-M07-19-NI-014
Drug Development
New Drug for Duchenne Muscular Dystrophy (DMD) Shows Promise
PAO-M07-19-NI-010
Diabetes
Preclinical Studies Bode Well for Diabetes Drug from Semma Therapeutics
PAO-M07-19-NI-009
T-Cell
Promoting T-Cell Survival
PAO-M07-19-NI-008
Drug Development
Spotlight on P2X3 Antagonists
PAO-M07-19-NI-006
FDA
FDA Considering Drug Designed to Improve Sexual Desire
PAO-M07-19-NI-004
Oncology
Imfinzi Improves Survival in the Phase III CASPIAN Trial in 1st-line Extensive-stage Small Cell Lung Cancer
PR-M07-19-NI-003
FDA Approval
FDA Approves First Treatment for Chronic Rhinosinusitis with Nasal Polyps
PR-M07-19-NI-003
Series B Financing
DayTwo Secures $31 Million In Series B Financing To Scale Microbiome Research Platform To Address Chronic Health Conditions
PR-M06-19-NI-059
CRISPR
CRISPR Gene Editing of Babies Could Take Place in Russia
PAO-M06-19-NI-021
Biosimilar Approval
Herceptin Biosimilar Approved in the U.S.
PAO-M06-19-NI-017
FDA Approval
FDA Approves Pembrolizumab for Metastatic Small Cell Lung Cancer
PR-M06-19-NI-038
Drug Development
Brain Organoids Could Speed Drug Development for Neurological Diseases
PAO-M06-19-NI-016
Immune Markers
Using Immune Markers to Identify Precancerous Cells
PAO-M06-19-NI-015
Diabetes
Common Glycemic Control Drug Could Have Other Significant Positive Effects for Type 2 Diabetes Patients
PAO-M06-19-NI-012
Drug Approval
Emflaza Now Approved for Treatment of Young Children
PAO-M06-19-NI-011
Strategic Relationship
IVERIC Bio Enters Into Strategic Manufacturing Relationship With Catalent’s Paragon Gene Therapy For Orphan Inherited Retinal Diseases
PR-M06-19-NI-034
Migraine Therapy
Mimicking Environmental Enrichment for Migraine Therapy
PAO-06-2019-CL-003
Clinical Trials
GBT Announces Efficacy Data from All Patients Enrolled in Phase 3 Study Sustained Improvements in Hemoglobin with Voxelotor
PR-M06-19-NI-025
Positive Results
Lilly Presents Positive Results for Taltz® vs. Humira®in Patients with Active Psoriatic Arthritis
PR-M06-19-NI-023
1
20
»
